Harry Welten
Angel Investor
Harry Welten is a Series A investor focused on Biotechnology and Medical. Harry has 20 years of international executive experience, more than 11 of which as a CFO in the biotech industry. Prior to joining Cytos, Mr. Welten was CFO at Nitec Pharma AG in Reinach, Switzerland, which merged with US-based Horizon Pharma Inc. and was listed on Nasdaq in 2011. From 2001 to 2009, he was CFO at Arpida AG, Basel, Switzerland,taking the company public in 2005 to the SIX Swiss Exchange and raising more than CHF 250 million in private and public offerings. Prior to joining Arpida, he held various senior management positions at UBS group including Director at UBS Warburg in New York. Before joining UBS, Mr. Welten was with ABB and DaimlerChrysler. He is a member of the Board of Directors of BiognoSYS AG, Horizon Pharma AG, and BioSupport AG, and a member of the foundation council of HBM Foundation. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons) from Columbia University, NY, USA.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Harry Welten invests in
Stages Harry Welten invests in
Countries Harry Welten invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $1.3M–$38M
Investment Focus
Industry
- Biotechnology 2 (100%)
- Medical 1 (50%)
- Health Care 1 (50%)
- Therapeutics 1 (50%)
- Clinical Trials 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Virometix is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases.In an increasingly global world there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases. Fastgrowing demands, health threats from newly arising complex viral and bacterial pathogens and increasingly stringent requirements for stability, safety and tolerability require new approaches to tackling current and future challenges.Rational molecular design, chemical synthesis and Virometix' proprietary Synthetic Virus-Like Particle platform technology allow for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability. | $1.3M / Series A / Sep 04, 2017 | ||
| Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can betranslated to virtually any protein in numerous clinical indications. | $37.5M / Series A / May 09, 2014 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Harry Welten invest in?
Harry Welten invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Harry Welten's check size?
Harry Welten typically joins rounds of $1.3M–$38M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Harry Welten participates in.
How do I contact Harry Welten?
Public channels for Harry Welten include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Harry Welten last invest?
The most recent investment recorded for Harry Welten closed in Sep 2017. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
